Remaining authorization is estimated: we derive it from reported spend, or convert a share authorization at the latest close. Check the linked filings.
Programs
Authorized on
Authorized
Remaining
Expires
Terms
Not found in filings
$600m
$35m
n/a
In November 2022, Adient’s Board of Directors authorized the repurchase of Adient’s ordinary shares up to an aggregate purchase price of $600 million with no expiration date.10-K filed 13-Nov-26
Not found in filings
$400m
$400mEST
n/a
In November 2026, the Board voted to increase the repurchase authorization by $400 million, bringing the total authorization to $1 billion with no expiration date.10-K filed 13-Nov-26
Open-market repurchases
Repurchased per month, USD (≈ shares × average price)